Daxor Corporation announced the appointment of Lisa Quartley as its first SVP, Marketing and Commercial Development. Ms. Quartley will be leading a newly focused and reinvigorated commercialization effort for the company's unique diagnostic technology with the goal of making direct blood volume measurement a standard of care. Within the past five years she has led consultancy-side strategic efforts for key brands at Genentech, Novartis, Bristol-Myers Squibb, and Eisai.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.76 USD | -3.10% | -7.94% | -8.75% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.75% | 4.21Cr | |
+7.69% | 1.33TCr | |
+11.85% | 954.97Cr | |
+2.65% | 574.14Cr | |
+7.30% | 527.12Cr | |
-0.71% | 510.95Cr | |
+26.36% | 498.93Cr | |
+20.18% | 458.88Cr | |
+1.45% | 397.67Cr | |
+5.29% | 397.26Cr |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Appoints Lisa Quartley as its First SVP, Marketing and Commercial Development